Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber - 04/08/16
Abstract |
Background |
In a natural field study, sublingual tablets of house dust mite (HDM) allergen extracts (STG320) were efficacious in treating HDM-associated allergic rhinitis.
Objectives |
We sought to assess the efficacy and safety of 3 doses of STG320 in an environmental exposure chamber.
Methods |
In this randomized, double-blind study, adults with HDM-associated allergic rhinitis were given a daily sublingual tablet containing placebo or STG320 at a dose of 500IR, 300IR, or 100IR (IR, index of reactivity) for 6 months. Participants recorded their rhinitis symptoms during 4-hour HDM EEC challenges at randomization and months 1, 2, 4, and 6. The primary efficacy end point was the change from baseline to end of treatment in the area under the curve of the rhinitis total symptom score (ChBLAUCRTSS 0-4h). Differences from the placebo group were analyzed by analysis of covariance. Adverse events (AEs) and routine safety parameters were recorded.
Results |
A total of 355 subjects were randomized to 1 of 4 groups: 500IR (n = 93), 300IR (n = 86), 100IR (n = 89), or placebo (n = 87). The least squares mean differences from placebo in ChBLAUCRTSS 0-4h for the 500IR, 300IR, and 100IR groups indicated a dose-dependent effect, with reductions in symptom scores of 33%, 29%, and 20%, respectively. The most frequent AEs were throat irritation and oral pruritus. There were no reports of anaphylaxis or reports consistent with severe laryngopharyngeal disorders and no use of epinephrine. AEs leading to premature discontinuations were more common in the 500IR group.
Conclusions |
A dose-dependent effect of sublingual HDM immunotherapy was demonstrated in this environmental exposure chamber study, supporting further development of this treatment.
Le texte complet de cet article est disponible en PDF.Key words : Allergen immunotherapy, allergic rhinitis, house dust mite, sublingual immunotherapy tablet, double-blind placebo-controlled trial, environmental exposure chamber, dose-ranging
Abbreviations used : AE, AIT, ARSS, ARTSS, AUC, AVASS, ChBL, EEC, HDM, IR, RTSS, TEAE, VAS
Plan
This study was funded by Stallergenes S.A., France. |
|
Disclosure of potential conflict of interest: M. Roux, A. Montagut, K. Abiteboul, A. Viatte, and R. K. Zeldin are employees of Stallergenes S.A. P. Devillier has received consulting fees from Stallergenes S.A. and has received honoraria for board membership, consultancy, lectures, and/or manuscript preparation from ALK, Almirall, Astra-Zeneca, Boehringer-Ingelheim, Chiesi, CLL Pharma, GlaxoSmithKline, Meda Pharma, Mundipharma, Novartis, Sandoz, Stallergenes S.A., and Teva. W. H. Yang has received research grants from Stallergenes S.A. |
Vol 138 - N° 2
P. 451 - août 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?